Medical management of hepatorenal syndrome

  • Andrew Davenport
  • , Jawad Ahmad
  • , Ali Al-Khafaji
  • , John A. Kellum
  • , Yuri S. Genyk
  • , Mitra K. Nadim

Research output: Contribution to journalReview articlepeer-review

35 Scopus citations

Abstract

Hepatorenal syndrome (HRS) is defined as the occurrence of renal dysfunction in a patient with end-stage liver cirrhosis in the absence of another identifiable cause of renal failure. The prognosis of HRS remains poor, with a median survival without liver transplantation of <6 months. However, understanding the pathogenesis of HRS has led to the introduction of treatments designed to increase renal perfusion and mean arterial blood pressure using vasopressors and albumin, which has led to improvement in renal function in ∼50% of patients.

Original languageEnglish
Pages (from-to)34-41
Number of pages8
JournalNephrology Dialysis Transplantation
Volume27
Issue number1
DOIs
StatePublished - Jan 2012

Keywords

  • albumin
  • ascites
  • hepatorenal
  • vasopressors

Fingerprint

Dive into the research topics of 'Medical management of hepatorenal syndrome'. Together they form a unique fingerprint.

Cite this